Key Advances in Non–Small Cell Lung Cancer From WCLC 2020

Tony Mok, MD


February 19, 2021

Tony Mok, MD, a leading expert in non–small cell lung cancer (NSCLC) from The Chinese University of Hong Kong, offers his perspective on the potentially practice-changing data presented at the IASLC 2020 World Conference on Lung Cancer.

First, he focuses on uncommon mutations in NSCLC, beginning with two studies in patients with EGFR exon 20 insertions whose tumors had progressed on platinum-based chemotherapy. Both mobocertinib and amivantamab showed clinically meaningful benefits, although their place in the treatment pathway remains open to question.

Prof. Mok next turns his attention to trastuzumab deruxtecan in HER2-overexpressing metastatic NSCLC, comparing its efficacy with that in patients with HER2 mutations, followed by a study of sotorasib in KRAS p.G12C-mutant tumors.

He closes by reporting on TALENT, which assessed a national lung cancer screening program in never-smokers in Taiwan.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.